Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

NCT04857164 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab combined with Chemotherapy

Sponsor

Yuankai Shi